https://www.thebodypro.com/tag/conference-coverage

Conference Coverage

The Latest

HIV Prevalence Among Non-Medicaid Expansion States

Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade

The lack of Medicaid expansion in the South is creating worse racial disparities in the U.S., according to researchers and medical providers discussing the HIV care cascade at CROI 2018.

More HIV Research Highlights From CROI 2018 Img

More HIV Research Highlights From CROI 2018

Three video interviews with federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.

Inching Towards an HIV Cure: bNAb and TLR-7 Agonist Reduce Viral Rebound Off-ART in Macaques Img

Inching Towards an HIV Cure: bNAb and TLR-7 Agonist Reduce Viral Rebound Off-ART in Macaques

Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses Img

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment Img

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment

New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification Img

No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification

Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.

HIV Research Highlights From First Day of CROI 2018 Img

HIV Research Highlights From First Day of CROI 2018

A Facebook Live interview with NIAID Division of AIDS director Carl Dieffenbach, Ph.D., about some of the key research findings presented during the first full day of sessions at CROI 2018.

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin Img

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.

High Uptake and Use of Vaginal Ring for HIV Prevention Observed in Open-Label Study Img

High Uptake and Use of Vaginal Ring for HIV Prevention Observed in Open-Label Study

Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to data presented at CROI 2018.